258281-02-6

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Hydroxyethyl)-2,5-dimethyl-1,2-dihydro-3H-pyrazol-3-one is used as a potential drug candidate for its antioxidant properties, which can help in scavenging free radicals and protecting against oxidative stress. This makes it a promising agent for the development of treatments targeting conditions associated with oxidative stress, such as neurodegenerative diseases and cardiovascular disorders.
Used in Anti-Inflammatory Applications:
In the pharmaceutical industry, DG13 is used as an anti-inflammatory agent due to its potential to inhibit the production of pro-inflammatory cytokines, thereby reducing inflammation. This property can be beneficial in the treatment of various inflammatory conditions, such as arthritis, asthma, and inflammatory bowel diseases.
Used in Cosmetic Industry:
4-(2-Hydroxyethyl)-2,5-dimethyl-1,2-dihydro-3H-pyrazol-3-one is used as an active ingredient in cosmetic products for its anti-aging properties. Its antioxidant and anti-inflammatory effects can help in reducing the visible signs of aging, such as wrinkles and fine lines, and promoting a more youthful appearance.
Used in Antioxidant Formulations:
In both the pharmaceutical and cosmetic industries, DG13 is used as an antioxidant in various formulations to protect cells and tissues from oxidative damage. Its ability to neutralize free radicals can contribute to the development of products that promote overall health and well-being, as well as improve the efficacy of other ingredients in the formulation.

Upstream product

• 517-23-7 3-acetyl-2-oxo-4,5-dihydrofuran 
• 60-34-4 methylhydrazine 

Relevant academic research and scientific papers

3-pyrazolone analogues of the 3-isoxazolol metabotropic excitatory amino acid receptor agonist homo-AMPA. Synthesis and pharmacological testing

We have previously shown that the higher homologue of (S)-glutamic acid [(S)-Glu], (S)-α-aminoadipic acid [(S)-α-AA] is selectively recognized by the mGlu2 and mGlu6 subtypes of the family of metabotropic glutamic acid (mGlu) receptors. Furthermore, a number of analogues of (S)-α-AA, in which the terminal carboxyl group has been replaced by various bioisosteric groups, such as phosphonic acid or 3-isoxazolol groups, have been shown to interact selectively with different subtypes of mGlu receptors. In this paper we report the synthesis of the 3-pyrazolone bioisosteres of α-AA, compounds (RS)-2-amino-4-(1,2-dihydro-5-methyl-3-oxo-3H-pyrazol-4-yl)butyric acid (1) and (RS)-2-amino-4-(1,2-dihydro-1,5-dimethyl-3-oxo-3H-pyrazol-4-yl)butyric acid (2). At a number of steps in the reaction sequences used, the reactions took unexpected courses and provided products which could not be transformed into the target compounds, and attempts to synthesize the 2,5-dimethyl isomer of 2, compound 3, failed. An X-ray crystallographic analysis of the intermediate 1,2-dihydro-4-(2-hydroxyethyl)-2,5-dimethyl-3H-pyrazol-3-one (5b) confirmed the expected regioselectivity of the reaction between methylhydrazine and α-acetylbutyrolactone (4). Neither 1 nor 2 showed significant effects at the different types of ionotropic glutamic acid receptors or at mGlu(1a) (group I), mGlu2 (group II), and mGlu(4a) and mGlu6 (group III) receptors, representing the three indicated groups of mGlu receptors.